Browsing Tag
Datopotamab deruxtecan
4 posts
TROPION-PanTumor03 trial reports breakthrough responses with DATROWAY and Rilvegostomig combo in bladder cancer
Discover how DATROWAY plus rilvegostomig is rivaling the EV-302 standard with high response rates in metastatic urothelial cancer.
Daiichi Sankyo (TSE: 4568) and AstraZeneca (NASDAQ: AZN) surge on Datroway’s historic first-line TNBC survival win
Find out how Datroway’s first-line TNBC survival win could rewrite chemotherapy-first playbooks and accelerate the ADC era in breast cancer—read the full analysis.
AstraZeneca’s breakthrough in lung cancer treatment: Datopotamab deruxtecan achieves promising survival rates
AstraZeneca’s datopotamab deruxtecan (Dato-DXd), a cutting-edge TROP2-directed antibody-drug conjugate, has demonstrated encouraging overall survival results in the TROPION-Lung01…
Datopotamab deruxtecan shows promise in Phase III trial for NSCLC
AstraZeneca and Daiichi Sankyo have announced promising results from the TROPION-Lung01 Phase III trial, highlighting datopotamab deruxtecan’s potential…